BVI has been recognized with four awards in the 2025 Medical Device Network Excellence Awards for achievements in Innovation, Research and Development, Investments, and Product Launches for its activities in advancing eye care technology, financial strategy, and product development.
The Medical Device Network Excellence Awards honor the most significant achievements and innovations in the medical devices industry. Powered by GlobalData’s business intelligence, the Awards recognize the people and companies leading change and shaping the future of the industry.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
BVI won the Innovation award in the Ophthalmic Implants category for introducing ISOFOCAL technology in its SERENITY and SERENITY Toric IOLs. It won the Research and Development award for advancing minimally invasive glaucoma treatment technology. Its successful capital raise and global expansion efforts earned BVI the Investments award in Strategic Growth category. Additionally, the launch of its next-generation intraocular lens portfolio led to the Product Launches award recognition in the Ophthalmic Implants category.
Breakthrough Innovation in Ophthalmic Implants: ISOFOCAL Technology and the SERENITY IOL Series
The Innovation award celebrates BVI’s pioneering development and integration of ISOFOCAL technology in its SERENITY and SERENITY Toric premium monofocal intraocular lenses. This patented technology delivers a 50% increase in depth of focus compared to standard monofocal IOLs, providing patients with both excellent distance and intermediate vision without compromising image quality or causing visual disturbances.
The SERENITY series stands out as the only IOLs to offer a personalized approach to vision correction, uniquely adjusting spherical aberration per lens power. The SERENITY Toric IOLs further enhance clinical outcomes with BVI’s exclusive double C-loop POD platform, engineered for superior rotational stability and precise astigmatism correction. These innovations simplify the surgical process for ophthalmic surgeons and support predictable, long-term results for patients. By building on the legacy of the ISOPURE family, BVI has set a new benchmark in intraocular lens design, reinforcing its commitment to advancing ophthalmic technology. The company’s focus on non-diffractive, light-efficient optics ensures uncompromised contrast sensitivity and minimizes unwanted visual phenomena, further supporting improved patient outcomes.
Advancements in glaucoma R&D: The Leos™ Laser Endoscopy Ophthalmic System
The Leos™ Laser Endoscopy Ophthalmic System, which has received the FDA 510(k) clearance, represents a significant development in minimally invasive glaucoma surgery, combining advanced laser technology with high-resolution endoscopic visualization. The Leos™ system introduces a novel mechanism of action by addressing aqueous humor production through a minimally invasive ab interno procedure. This approach expands treatment options for glaucoma, particularly for patients in earlier stages of the disease and those with diverse glaucoma types.
A key aspect of the Leos™ system is its integration of unique endoscopic capabilities, which provide vibrant, high-quality visualization of eye anatomy. This enhanced visualization is designed to improve surgical precision and safety, supporting better outcomes for patients. The system’s intuitive design allows for seamless incorporation into existing surgical workflows, which can help reduce barriers to adoption among clinicians.
BVI’s commitment to evidence-based innovation is further demonstrated by the emerging data from randomized controlled trials supporting the Leos™ system’s clinical value. These trials provide important validation of the system’s safety and efficacy, reinforcing its potential role in glaucoma management. With glaucoma projected to affect over 111 million people globally by 2040, the introduction of the Leos™ system addresses a pressing global health challenge by offering a new solution applicable across a wide spectrum of glaucoma cases.
The company anticipates launching Leos commercially in the U.S. in the coming months.
“We are honoured to receive this recognition for our groundbreaking work in glaucoma. The Leos™ Laser Endoscopy Ophthalmic System represents years of dedicated research, innovation, and collaboration to bring a minimally invasive solution that integrates advanced laser and endoscopic technologies. LEOS builds on decades of clinical experience, adding a superior level of usability and fitting seamlessly into fast-paced glaucoma and cataract practices. This award reinforces our commitment to pushing the boundaries of what’s possible in glaucoma care and improving patient outcomes worldwide.”
– Mikhail Boukhny, Senior Vice-President, Research & Development
Strategic capital investment and global expansion
BVI’s recognition in the Investments category is underpinned by its successful $1 billion capital raise, which was completed in partnership with its financial sponsor TPG. This capital raise fully refinanced the company’s existing debt and significantly strengthened its financial position, providing a solid foundation for accelerated growth and innovation. The scale of this investment reflects strong market confidence in BVI’s leadership and long-term strategic direction.
The capital infusion has enabled BVI to pursue several strategic initiatives. Notably, the company has expanded its manufacturing capabilities in Europe to meet rising global demand for ophthalmic devices. The establishment of new entities, such as BVI Poland, exemplifies BVI’s commitment to global expansion and operational scalability. The new office in Krakow serves as a Centre of Excellence, bringing together teams across finance, customer operations, regulatory affairs, quality assurance, HR, and talent acquisition. This expansion is designed to drive efficiency, process improvement, and workload consolidation, while also supporting talent acquisition and retention.
The investment has also facilitated the launch of new product lines, such as the SERENITY and SERENITY Toric premium monofocal intraocular lenses (IOLs), directly linking financial strategy to tangible market outcomes. Furthermore, the strengthened financial position enhances BVI’s ability to pursue strategic acquisitions and invest in organizational growth, including the recruitment and retention of top industry talent. These combined efforts position BVI to respond effectively to evolving market needs and to continue its trajectory as a significant player in the global ophthalmic devices sector.
“This award highlights the incredible momentum behind BVI’s growth journey. The successful $1 billion capital raise reflects the strong confidence our financial sponsor TPG has in our vision, strategy, and leadership. With this strengthened financial position, we are well-equipped to accelerate innovation, expand our global footprint, and drive long-term value for patients, customers, and stakeholders alike.”
– Todd Patriacca, Chief Finance Officer
SERENITY IOLs: Launching next-generation ophthalmic implants
BVI’s award for Product Launches in Ophthalmic Implants recognizes the introduction of the SERENITY and SERENITY Toric premium monofocal IOLs. These products build on BVI’s legacy of innovation in intraocular lens technology, representing the second generation of the ISOPURE family first introduced in 2019. The SERENITY IOLs incorporate patented ISOFOCAL optic technology, which is designed to provide both distance and intermediate vision. This technology increases the depth of focus by approximately 50% compared to standard monofocal IOLs, offering patients improved visual outcomes without compromising image quality or causing visual disturbances.
A distinctive feature of the SERENITY product line is its ability to adjust spherical aberration per lens power, delivering a more personalized vision correction for patients. The SERENITY Toric IOLs further enhance patient outcomes by utilizing the exclusive double C-loop POD platform. This platform is engineered for rotational stability and precise astigmatism correction, simplifying the surgical process for ophthalmic surgeons and supporting predictable, long-term results.
The launch of the SERENITY and SERENITY Toric IOLs was executed through a comprehensive strategy, including high-profile unveilings at major industry events such as the European Society of Cataract and Refractive Surgeons (ESCRS) congress. The product introduction was supported by global marketing initiatives and educational efforts aimed at surgeons, resulting in strong adoption and positive feedback from early users. The SERENITY series addresses a rapidly growing market segment, with intermediate-optimized IOLs projected to see a 15% compound annual growth rate. By responding to evolving patient and surgeon needs, BVI has reinforced its position in the ophthalmic implant market and demonstrated its ongoing commitment to product innovation.
“The launch of the SERENITY and SERENITY Toric premium monofocal intraocular lenses (IOLs) has been a defining moment for BVI, marking a potential revolution in the standard of cataract care for monofocal procedures. Leveraging BVI’s patented ISOFOCAL optical technology to elegantly balance depth of field (DoF) and image quality, these lenses deliver distance vision equivalent to traditional monofocal lenses while providing outstanding intermediate vision up to 66 cm. This meets the rapidly growing demand for intermediate-optimized solutions and is reshaping expectations for intraocular lens performance among both patients and surgeons. This award is a tribute to the incredible cross-functional teams whose launch strategy seamlessly combined innovation, surgeon engagement, and market impact.”
– Andy Chang, Chief Commercial Officer
“At BVI, innovation is in our DNA. The development of the SERENITY and SERENITY Toric IOLs, with their breakthrough ISOFOCAL technology, exemplifies our commitment to delivering solutions that raise the standard of care and address evolving patient needs. This recognition reflects the passion and dedication of our teams around the world, and it reinforces BVI’s position as a leader and innovator within the ophthalmic space.”
– Shervin Korangy, President and Chief Executive Officer
Company Profile
BVI is at the forefront of innovation in ophthalmic surgery, delivering cutting-edge solutions that enhance patient care and improve vision outcomes. With a global product presence in over 90 countries, the company tailors its eye care offerings to meet the unique needs of local markets, while contributing to the betterment of global eye health.
BVI partners with ophthalmic surgeons to continuously push the boundaries of what is possible in vision restoration. The company’s commitment to excellence has enhanced the vision of millions of patients globally, by supporting surgical teams, either directly or through its trusted network of distributors.
BVI’s portfolio touched the lives of millions of patients around the world with a presence in 15 countries, 8 manufacturing plants, 7 R&D centers, and 4 distribution centers. BVI addresses a wide range of ophthalmic procedures such as cataracts, refractive error, glaucoma, retinal disease, and dry eye.
Contact Details
David Chavez, Global Communications Lead
dchavez@bvimedical.com
+1 (857) 869 8706
Links
Website: https://www.bvimedical.com/
